Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
$99.99
$97.65
$45.50
$100.00
$6.17B0.551.56 million shs107 shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$15.41
+2.4%
$14.79
$11.51
$21.50
$2.62B0.52101,508 shs81,977 shs
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$48.59
-0.5%
$48.25
$29.02
$58.38
$3.87B0.5861,793 shs1.16 million shs
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
$172.36
$171.30
$21.83
$172.46
$6.58B1.421.09 million shsN/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$9.08
-0.4%
$7.44
$4.62
$13.47
$571.10M0.291.29 million shs842,694 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
-0.33%-1.05%+9.30%-6.29%-12.09%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-2.01%-1.53%+0.04%+4.81%+59.71%
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-0.33%-1.94%+40.31%+16.03%-16.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1.784 of 5 stars
2.04.00.00.01.80.01.9
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
4.3452 of 5 stars
4.31.00.04.41.80.81.3
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
3.2048 of 5 stars
2.02.00.04.02.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
0.00
N/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.00
Hold$19.0023.30% Upside
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2.67
Moderate Buy$65.0033.77% Upside
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
0.00
N/AN/AN/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
2.00
Hold$8.93-1.62% Downside

Current Analyst Ratings Breakdown

Latest SAGE, ARNA, HCM, RETA, and PTCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.00
6/17/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$80.00
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$9.00 ➝ $8.50
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetHold ➝ Hold$8.00 ➝ $9.00
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$12.00
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$8.00 ➝ $8.50
6/16/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/27/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.00
5/13/2025
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/9/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$55.00 ➝ $68.00
5/8/2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
$50K123,305.67N/AN/A$10.94 per share9.14
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$630.20M4.26$0.29 per share52.40$4.43 per share3.48
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$806.78M4.77N/AN/A($14.24) per share-3.41
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
$23.48M280.05N/AN/A($1.79) per share-96.29
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$41.24M13.79N/AN/A$7.60 per share1.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
-$616.43M-$10.13N/AN/AN/AN/A-69.83%-62.35%N/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$37.73MN/A0.0010.55N/AN/AN/AN/A7/29/2025 (Estimated)
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
-$363.30M$6.517.46N/AN/A33.56%-78.56%32.11%8/6/2025 (Estimated)
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
-$311.90MN/A0.00N/AN/AN/A-922.50%-73.39%N/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$400.67M-$5.80N/AN/AN/A-747.63%-68.99%-60.67%7/30/2025 (Estimated)

Latest SAGE, ARNA, HCM, RETA, and PTCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
$0.85$10.04+$9.19N/A$437.16 million$1.18 billion
4/29/2025Q1 2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/AN/AN/AN/AN/A
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
N/AN/AN/AN/AN/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
0.05
8.59
8.59
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.08
2.83
2.70
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
3.89
3.85
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
0.84
3.21
3.19
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/A
9.13
9.13

Institutional Ownership

CompanyInstitutional Ownership
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
83.77%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
N/A
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
N/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
99.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arena Pharmaceuticals, Inc. stock logo
ARNA
Arena Pharmaceuticals
44861.66 million60.17 millionOptionable
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,811174.32 million168.05 millionNot Optionable
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
1,41079.26 million74.90 millionOptionable
Reata Pharmaceuticals, Inc. stock logo
RETA
Reata Pharmaceuticals
32138.15 million27.93 millionOptionable
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
69062.62 million59.18 millionOptionable

Recent News About These Companies

Sage lays off entire staff of 338 amid takeover by Supernus

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arena Pharmaceuticals stock logo

Arena Pharmaceuticals NASDAQ:ARNA

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$15.41 +0.36 (+2.39%)
Closing price 04:00 PM Eastern
Extended Trading
$15.38 -0.03 (-0.19%)
As of 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

PTC Therapeutics stock logo

PTC Therapeutics NASDAQ:PTCT

$48.59 -0.25 (-0.51%)
Closing price 04:00 PM Eastern
Extended Trading
$48.58 -0.01 (-0.02%)
As of 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Reata Pharmaceuticals stock logo

Reata Pharmaceuticals NASDAQ:RETA

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Sage Therapeutics stock logo

Sage Therapeutics NASDAQ:SAGE

$9.08 -0.04 (-0.44%)
Closing price 04:00 PM Eastern
Extended Trading
$9.05 -0.03 (-0.29%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.